Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the Company has recently received five awards recognizing its corporate accomplishments and digital marketing efforts, including the prestigious PM360 Trailblazer Award for Company of the Year in the category of Best Specialty Pharma/Biotechnology Company. The Trailblazer Awards highlight outstanding achievement and innovation in healthcare marketing. In particular, Acorda was recognized for its pursuit of excellence in three separate areas: marketing and advertising, talent development and social responsibility. The award is presented by the widely-read PM360 magazine, a resource for marketing decision-makers in the pharmaceutical, biotech, and medical device industries. Award decisions are made by the PM360 Editorial Advisory Board, composed of distinguished healthcare marketing and other industry experts. “We have more than 400 associates at Acorda who share the purpose of improving the lives of people with neurological diseases,” said Ron Cohen, M.D., Acorda's President and CEO. “This is a challenging goal that can only be achieved through commitment, perseverance and collaboration. It’s a privilege for all of us at Acorda to be recognized by PM360 for the contributions we are making to advance the care of people with these devastating illnesses.” Acorda also was honored with three industry awards by three other prestigious organizations. The American Business Association recognized the Company’s corporate web site, www.acorda.com , with its 2013 Gold Stevie Award in the category of pharmaceutical website. The Web Marketing Association selected both the consumer and healthcare professional sections of Acorda’s product website, www.ampyra.com , as winners of the 2013 Pharmaceuticals Standard of Excellence Award. The Web Marketing Association’s WebAward program is the longest running annual website award competition. Medical Marketing & Media recognized ampyra.com with a Silver MM&M Award in the category of best branded website for consumers. This year's judging process included two comprehensive rounds of scoring by more than 100 independent judges who are seasoned industry professionals. Dr. Cohen said, “Bringing innovative medications to market is just one element of our mission to improve patient lives. We also seek to provide a broad range of important health information to patients, healthcare professionals and patient advocacy communities, and our online initiatives are key elements of these programs. Being acknowledged by our peers for the caliber of these initiatives is both satisfying and hugely motivating.”
About Acorda TherapeuticsFounded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological conditions. Acorda markets three FDA-approved therapies including: AMPYRA®(dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (MS); ZANAFLEX CAPSULES® (tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the management of spasticity; and QUTENZA® (capsaicin) 8% Patch, for the management of neuropathic pain associated with postherpetic neuralgia. AMPYRA is marketed outside the United States as FAMPYRA ® (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda. Acorda has one of the leading pipelines in the industry of novel neurological therapies. The Company is currently developing six clinical-stage therapies and one preclinical stage therapy that address a range of disorders including post-stroke deficits, epilepsy, cerebral palsy, stroke, peripheral nerve damage, spinal cord injury, neuropathic pain, and heart failure. For more information, please visit the Company’s website at: www.acorda.com. Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including our ability to successfully market and sell Ampyra in the U.S.; third party payers (including governmental agencies) may not reimburse for the use of Ampyra or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of Ampyra or from our other research and development programs, including Diazepam Nasal Spray or any other acquired or in-licensed programs; we may not be able to complete development of, obtain regulatory approval for, or successfully market Diazepam Nasal Spray or other products under development; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain regulatory approval of or to successfully market Fampyra outside of the U.S. and our dependence on our collaboration partner Biogen Idec in connection therewith; competition, including the impact of generic competition on Zanaflex Capsules revenues; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; failure to comply with regulatory requirements could result in adverse action by regulatory agencies; and the ability to obtain additional financing to support our operations. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities & Exchange Commission. Acorda may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this release are made only as of the date hereof, and Acorda disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this release.